This epigenetic modulation by acetylated KLF5 unveils a therapeutic opportunity; the concurrent administration of docetaxel and the CXCR4 inhibitor plerixafor has shown efficacy in curbing ac‐KLF5‐driven bone metastasis and enhancing tumor response to chemotherapy.236. The gene discussed is CXCR4; the disease is neoplasm.